Issue 72

DMT and Major Depressive Disorder

At the PSYCH Symposium on 11 May, industry leaders will connect and collaborate to expedite access to psychedelic-based healthcare across Europe.

Small Pharma is conducting the first ever clinical trial with DMT therapy to treat Major Depressive Disorder (MDD), with Chief Medical and Scientific Officer Dr Carol Routledge speaking at the event.

More than 280 million people suffer from depression worldwide, and Major Depressive Disorder costs European economies over US$130 billion each year.

As a result, medical innovation could have dramatic benefits both socially and economically.

PSILOCYBIN DISPENSARIES OPERATING OPENLY IN DOWNTOWN VANCOUVER

Mirroring the early days of cannabis reform in Canada, psilocybin dispensaries are opening in Vancouver’s city centre.

JOHNS HOPKINS, YALE AND NEW YORK UNIVERSITY COLLABORATE ON TRAINING

The academic institutions have launched a collaboration to boost therapist numbers and access to psychedelic medicine.

BUSINESS AND INVESTMENT

Novamind to host MindMed’s Phase II LSD trial.

MINDCURE announces leadership overhaul and cutbacks.

How capital markets are fuelling psychedelic industry growth.

Nova Mentis raises C$1.4m in private placement.

MindBio Therapeutics invests NZ$2.3m to advance microdosing trials.

BioMind approved for DMT trial in Brazil.

Small Pharma expands clinical trials for 2022.

Enveric Biosciences files patents for novel tryptamines.

PSYCH Symposium: London 2022

PSYCH Symposium brings leading figures from policy, science and business together to shape the future of psychedelic healthcare in Europe.

Speakers include:

Professor David Nutt – Founder, Drug Science
Rick Doblin – Founder, MAPS
Crispin Blunt MP – Chair, Conservative Drug Policy Reform Group

Secure your ticket today to connect with industry influencers and learn from the sector’s thought leaders as we expedite access to psychedelic medicine.

For partnership opportunities, please visit the website.

Ticket registration

SCIENCE AND RESEARCH

Psychedelic medicines studied as treatment for biophobia.

Ketamine for suicidal ideation: heed lessons from opiate epidemic.

Could psilocybin be a treatment for mental illness?

The state of psychedelic research at Harvard University.

REGULATION AND LEGISLATION

How Oregon will provide psychedelic medicine outside healthcare.

Washington legislature approves $200,000 funding for psilocybin research.

Georgia lawmakers file resolution to study psychedelic medicines.

Head of Oregon’s Psilocybin Advisory Board resigns over conflict of interest.

Maryland holds hearing on state psychedelic research fund.